No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

BlackBerry Strengthens Medical Device Software Portfolio with QNX Hypervisor 2.2 for Safety

New Release Helps Companies Deliver Safety-Certified Medical Devices to Market Faster

Editor: What To Know

  • 2 for Safety, medical device manufacturers and other embedded system suppliers are empowered with ultimate design flexibility and scalability to consolidate multiple systems with mixed criticality and different operating environments onto a single hardware platform, reducing both the initial development and long-term costs of ownership for a wide variety of embedded systems in industries such as industrial, automotive, transportation, heavy machinery, rail and robotics and more.
  • regulatory scrutiny following the revelation of numerous medical device security vulnerabilities as of late, with the Food and Drug Administration (FDA) releasing draft cybersecurity guidance on medical devices alongside the introduction of two new pieces of legislation – the Protecting and Transforming Cyber Health Care (PATCH) Act and the Healthcare Cybersecurity Act, all of which seek to proactively strengthen cybersecurity healthcare protections and protect lives.
  • “At a time when embedded device developers are in a race to adopt the latest technologies to meet feature demands while balancing mixed criticality functions, the safe interoperation of an array of operating systems has never been so important.

BlackBerry Limited today announced the release of the QNX® Hypervisor 2.2 for Safety, the latest edition of the company’s safety-certified, real-time embedded hypervisor product, designed to enable the healthcare industry to deliver safe, secure medical devices and applications to market faster.

In addition to being certified to the latest ISO 26262 ASIL D standard for automotive and IEC 61508 SIL3 for electronic systems, the QNX Hypervisor 2.2 for Safety is recognized with the highest functional safety standard for medical device software – IEC 62304 Class C compliance – from the independent auditors at TÜV Rheinland. The new release comes at a time of increased U.S. regulatory scrutiny following the revelation of numerous medical device security vulnerabilities as of late, with the Food and Drug Administration (FDA) releasing draft cybersecurity guidance on medical devices alongside the introduction of two new pieces of legislation – the Protecting and Transforming Cyber Health Care (PATCH) Act and the Healthcare Cybersecurity Act, all of which seek to proactively strengthen cybersecurity healthcare protections and protect lives.

“Medical device manufacturers operate in an environment filled with intense market pressures, stringent safety regulations and concerns about cyberthreats,” said Grant Courville, Vice President, Products and Strategy at BlackBerry QNX. “BlackBerry QNX solutions are used in more than 50 types of medical devices and with the release of the QNX Hypervisor 2.2 for Safety, embedded developers have a software foundation that they can continue to count on which has been specifically designed for safety, security and reliability, enabling them to overcome many challenges at once.”

“At a time when embedded device developers are in a race to adopt the latest technologies to meet feature demands while balancing mixed criticality functions, the safe interoperation of an array of operating systems has never been so important. The latest release of the QNX Hypervisor for Safety brings together pre-certifications across key industry standards including IEC 62304 Class C for medical with additional support needed for high-performance computing. This solution can help deliver responsive user experiences and better time to market while giving organizations confidence that they can achieve their safety goals,” said Chris Rommel, Executive Vice President, IoT & Industrial Technology at VDC Research.

With the QNX Hypervisor 2.2 for Safety, medical device manufacturers and other embedded system suppliers are empowered with ultimate design flexibility and scalability to consolidate multiple systems with mixed criticality and different operating environments onto a single hardware platform, reducing both the initial development and long-term costs of ownership for a wide variety of embedded systems in industries such as industrial, automotive, transportation, heavy machinery, rail and robotics and more.

Medical device companies globally trust BlackBerry QNX software for a broad range of life-critical and graphics-rich medical applications including surgical robots, infusion pumps and pacemakers. BlackBerry QNX has a broad portfolio of embedded system software designed for mission-critical implementations, including the QNX® Hypervisor and the QNX® Neutrino® Real-time Operating System, in addition to middleware and development tools. Safety-certified variants of the QNX® OS for Safety are also available.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy